New PTAB Precedent Panel Conducts First Hearing
Contributed by Ropes & Gray. Originally published on Patexia; republished here as part of the LexDana archive.
Issue Joinder Practices Poised to Reset
As previously discussed, the Patent Trial & Appeal Board (PTAB) is now reconsidering its issue joinder practices. These practices were the subject of significant debate internal to the Board a few years back. The inability of the Board to arrive at a majority consensus on whether issue joinder was permitted by the AIA statutes led to the now infamous “panel stacking” decisions. These expanded panel decisions provided a brute force solution to the conflicting positions on the question of issue joinder, a de facto precedent of sorts.
With the new Precedential Opinion Panel, or “POP,” allowing for a more streamlined process for making precedent, the Board seems poised to drive official PTAB precedent on this question — but in a new direction.
Where the previous decisions found issue joinder to be consistent with the AIA statutes, the recent decision in Proppant Express Investments, LLC, Proppant Express Solutions, LLC v. Oren Technologies, LLC, (IPR2018-00914) finds it is not consistent. Since my initial post last November, amicus briefing has been accepted and an oral hearing conducted on Thursday, January 31st.
The amicus briefing (below) presents varying views of industry as well as individuals, but the writing appears to be on the wall that issue joinder will soon be officially outlawed by the POP’s first precedential decision.
Amicus submissions:
Scott A. McKeown is an author of the Patents Post Grant
More insights
Fresh From the Bench: Latest Precedential Patent Case
Ridge Corp. et al. v. Kirk NationaLease Co. et al. , Appeal No. 2025-1254 (Fed. Cir. July 13, 2026) In its only precedential patent opinion last week, the Federal Circuit considered an appeal of a preliminary injunction issued by the U.S. District Court…
Fresh From the Bench: Latest Precedential Patent Cases
CASE OF THE WEEK Wyeth LLC v. AstraZeneca Pharmaceuticals LP , Appeal No. 2024-2325 (Fed. Cir. July 9, 2026) In our Case of the Week, the Federal Circuit affirmed a district court ruling reversing a $107.5 million jury verdict against AstraZeneca in a case…
Enanta Pharmaceuticals, Inc. v. Pfizer Inc., Appeal No. 2025-1427 (Fed. Cir. Jun. 23, 2026)
CASE OF THE WEEK Enanta Pharmaceuticals, Inc. v. Pfizer Inc., Appeal No. 2025-1427 (Fed. Cir. Jun. 23, 2026) In our Case of the Week, the Federal Circuit affirmed summary judgment invalidating all claims of Enanta’s Patent No. 11,358,953 as…